The transaction does not include ABL inc. (US manufacturing site located in Rockville, Maryland), an independent, fully operational CDMO offering preclinical and clinical Phase I/II manufacturing, US based GMP production across viral vectors, vaccines, oncolytics, and immunotherapies.
